HIV treatment bulletin

RSS Atom • ISSN 1472-4683 • Subscribe • About

2003

Next page

• Volume 4 Number 10 December 2003/January 2004 PDF PDFs - 1 December 2003

• Volume 4 Number 10 December 2003 Editorial - 1 December 2003

• 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw Conference reports - Conference index - EACS 9 Warsaw 2003 - 1 December 2003

• Lower doses of d4T produce similar efficacy and reduced side effects Conference reports - Lipodystrophy and metabolic complications - Side effects - EACS 9 Warsaw 2003 - 1 December 2003

• Switching from efavirenz to nevirapine to avoid CNS side effects Antiretrovirals - Conference reports - Side effects - 1 December 2003

• Interruption of treatment is safe for those who started too early Conference reports - Treatment strategies - EACS 9 Warsaw 2003 - 1 December 2003

• T20 is cost effective for UK purchasers Antiretrovirals - Conference reports - EACS 9 Warsaw 2003 - 1 December 2003

• Intrauterine exposure to efavirenz Conference reports - PMTCT and maternal health - Side effects - Women's health - EACS 9 Warsaw 2003 - 1 December 2003

• African patients and adherence in the UK Antiretrovirals - Conference reports - 1 December 2003

• Five-year results of Kaletra-based therapy in treatment-naïve HIV patients Antiretrovirals - Conference reports - EACS 9 Warsaw 2003 - 1 December 2003

• IL-2 effectively increases CD4 count in people with low CD4 nadir Basic science and immunology - Conference reports - EACS 9 Warsaw 2003 - 1 December 2003

• Hepatitis coinfection: incidence in Europe and response to transplant Conference reports - Hepatitis coinfection - EACS 9 Warsaw 2003 - 1 December 2003

• Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL) Antiretrovirals - Cancer and HIV - Conference reports - EACS 9 Warsaw 2003 - 1 December 2003

• Access to treatment – some progress… Treatment access - 1 December 2003

• WHO approves combination pills Treatment access - 1 December 2003

• South African Competition Commission finds GSK and BI responsible for ‘excessive pricing’ and ‘abuse of market position’ Treatment access - 1 December 2003

• FTC (emtricitabine, Emtriva) approved in Europe Antiretrovirals - 1 December 2003

• EMEA recommend approval for atazanavir for treatment experienced patients Antiretrovirals - 1 December 2003

• Fosamprenavir (Lexiva) approved in US Antiretrovirals - 1 December 2003

• Polylactic acid (New-Fill) repairs facial wasting and improves quality of life Lipodystrophy and metabolic complications - 1 December 2003

• US paediatric, adult and maternal-child guidelines updated Antiretrovirals - 1 December 2003

• Increased risk of myocardial infarction associated with duration of protease inhibitor treatment Side effects - 1 December 2003

• UK guidelines for treating coinfection with HIV and hepatitis B or C published online Hepatitis coinfection - 1 December 2003

• Kidney and liver transplantation in HIV-infected patients: case presentations and review Hepatitis coinfection - 1 December 2003

• London epidemic of sexually transmitted hepatitis C Hepatitis coinfection - 1 December 2003

• Dramatic decline in mortality, disease progression and hospital admissions in children with HIV infection in the UK and Ireland Paediatric care - 1 December 2003

• New tool for assessing risks of disease progression and death based on age, CD4 percentage and viral load in HIV-infected children Paediatric care - 1 December 2003

• VaxGen AIDSVAX vaccine fails in Thailand Vaccines and microbicides - 1 December 2003

• Access to HIV treatment in Eastern Europe Treatment access - 1 December 2003

• Conferences On the web - 1 December 2003

• Online medical lectures On the web - 1 December 2003

• Newsletters and reports On the web - 1 December 2003

• HIV and hepatitis coinfection On the web - 1 December 2003

• Other news On the web - 1 December 2003

• Volume 4 Number 9 November 2003 Editorial - 1 November 2003

• Important safety information: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI combination containing ddI, 3TC, and tenofovir DF Treatment alerts - 1 November 2003

• 13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi Conference reports - Conference index - ICASA 13th 2003 - 1 November 2003

• STIs in resource limited settings Conference reports - Treatment strategies - ICASA 13th 2003 - 1 November 2003

• 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago Conference reports - Conference index - ICAAC 43rd Chicago 2003 - 1 November 2003

• ddI may retain activity in nucleoside experienced patients Antiretrovirals - Conference reports - ICAAC 43rd Chicago 2003 - 1 November 2003

• Studies and strategies with existing drugs Antiretrovirals - Conference reports - Treatment strategies - ICAAC 43rd Chicago 2003 - 1 November 2003

• Incremental progress with new antiviral drugs Antiretrovirals - Conference reports - ICAAC 43rd Chicago 2003 - 1 November 2003

• Newer nucleoside analogues show fewer adverse effects Conference reports - Side effects - ICAAC 43rd Chicago 2003 - 1 November 2003

• Interaction between amprenavir and lopinavir thwarts triple PI salvage PK and drug interactions - 1 November 2003

• Vitamin C induces P4503A4 and reduces indinavir levels PK and drug interactions - 1 November 2003

• Indinavir levels reduced by omeprazole PK and drug interactions - 1 November 2003

• Boosted saquinavir PK in once-daily regimes PK and drug interactions - 1 November 2003

• Tenofovir drug-drug interactions PK and drug interactions - 1 November 2003

• Summary of other PK studies PK and drug interactions - 1 November 2003

• Global AIDS spending must double by 2005, says gloomy UN Treatment access - 1 November 2003

• GARPP requests permission from Boehringer to import generic nevirapine Treatment access - 1 November 2003

• Canada decides to lead the way in exempting AIDS drugs from patent laws Treatment access - 1 November 2003

• Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule Antiretrovirals - 1 November 2003

• Another triple nuke failure: abacavir/ddI/d4T Antiretrovirals - 1 November 2003

• FDA announces changes to ritonavir package insert Antiretrovirals - 1 November 2003

• Treatment interruption prior to five-drug regime shows no benefit at 48 weeks Treatment strategies - 1 November 2003

• Failure of alternating week-on and week-off therapy Treatment strategies - 1 November 2003

• Canadian study shows increased interventional cardiovascular procedures associated with HAART Lipodystrophy and metabolic complications - 1 November 2003

• Valacyclovir is effective prophylaxis against herpes simplex Opportunistic infections and complications - 1 November 2003

• Antiviral dynamics and sex differences of AZT and 3TC triphosphate concentrations Women's health - 1 November 2003

• Women have a greater immunological response to effective HAART Women's health - 1 November 2003

• Use of rapid HIV tests in labour PMTCT and maternal health - 1 November 2003

• Eighteen-month findings of HIVNET 012 PMTCT and maternal health - 1 November 2003

• Rituximab as single agent reversed paediatric Non-Hodgkins Lymphoma (NHL) Paediatric care - 1 November 2003

• Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants Paediatric care - 1 November 2003

• Coinfected patients may require longer HCV treatment, irrespective of genotype Hepatitis coinfection - 1 November 2003

• New recommended standards of care for NHS services Other news - 1 November 2003

• Vatican says HIV can pass through condoms Other news - 1 November 2003

• Conferences On the web - 1 November 2003

• Newsletters and reports On the web - 1 November 2003

• HIV and hepatitis coinfection On the web - 1 November 2003

• Volume 4 Number 9 November 2003 PDF PDFs - 1 November 2003

• Volume 4 Number 8 October 2003 Editorial - 1 October 2003

• Important new pharmacokinetic data for atazanavir sulfate (Reyataz) in combination with tenofovir disoproxil fumarate (Viread) Treatment alerts - 1 October 2003

• British 2003 HIV treatment guidelines are published online Guidelines - 1 October 2003

• South Africa delays deregistering nevirapine Treatment access - 1 October 2003

• Disagreement greets a new deal on patent protection and generic drugs for poor countries Treatment access - 1 October 2003

• TRIPS agreement will not save lives Treatment access - 1 October 2003

• Joint statement by 14 NGOs dismisses TRIPS deal as a ‘gift bound in red tape’ Treatment access - 1 October 2003

• An activist’s view from the WTO meeting in Cancun Treatment access - 1 October 2003

• South African cabinet rules that public hospitals should provide ARVs Treatment access - 1 October 2003

• Indian government taken to court over lack of treatment Treatment access - 1 October 2003

• 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago Conference reports - Conference index - ICAAC 43rd Chicago 2003 - 1 October 2003

• South African AIDS Conference, 3-6 August 2003, Durban Conference reports - Conference index - South African AIDS Conference 2003 - 1 October 2003

• Township project is a model for care in resource poor settings Conference reports - Treatment access - South African AIDS Conference 2003 - 1 October 2003

• Projects band together to buy lowest-cost generic drugs Conference reports - Treatment access - South African AIDS Conference 2003 - 1 October 2003

• MTCT-Plus operates in Cote D’Ivoire, Kenya, Mozambique, Rwanda, South Africa, Thailand, Uganda and Zambia Conference reports - PMTCT and maternal health - South African AIDS Conference 2003 - 1 October 2003

• Further reports from 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July 2003 Conference reports - Conference index - IAS 2 Paris 2003 - 1 October 2003

• New atazanavir information Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 October 2003

• Boosted PI therapy antiretrovirals in treatment-experienced patients: SQV/r, ATV, ATV/r Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 October 2003

• HIV viral dynamics: viral fitness, genetic diversity, progression, co-receptor use Basic science and immunology - Conference reports - Virology - IAS 2 Paris 2003 - 1 October 2003

• Pulmonary hypertension: finally a treatment trial! Conference reports - Virology - IAS 2 Paris 2003 - 1 October 2003

• New guidelines for the evaluation and management of dyslipidaemia in HIV patients on HAART Lipodystrophy and metabolic complications - 1 October 2003

• Treatments for lipoatrophy. Are there improvements? Are they noticeable? Lipodystrophy and metabolic complications - 1 October 2003

• Rosiglitazone significantly increases triglyceride and cholesterol levels and does not improve HAART-associated lipoatrophy Lipodystrophy and metabolic complications - 1 October 2003

• US approves and Europe rejects Serostim (recombinant growth hormone) for treatment of HIV-related wasting Lipodystrophy and metabolic complications - 1 October 2003

• Testosterone therapy prevents loss of lean body mass, improves mood and libido in HIV positive women and increases bone mineral density in HIV positive men Side effects - 1 October 2003

• Only time with HIV infection and not specific antiretroviral therapy is associated with decreased bone mineral density Side effects - 1 October 2003

• IL-2 induced increases in CD4 counts are blunted by use of prednisone Basic science and immunology - 1 October 2003

• Treatment interruption shows no benefit in drug-resistant HIV infection Treatment strategies - 1 October 2003

Next page